Cellares raises $82M to drive work on cell therapy 'factory-in-a-box'

May 6, 2021 8:15am
Cellares has now received a total of $100 million in funding to develop its cell therapy "factory-in-a-box." (Cellares Corporation)
As cell therapies take the cancer world by storm, drugmakers are on the prowl for the latest and greatest ways to produce the complex medicines. Life sciences technology firm Cellares thinks the answer could fit in a box—a factory-in-a-box, to be precise—and the company just raised $82 million to take that work to the next level.
Armed with a fresh series B, Cellares now has $100 million in total funding to develop the Cell Shuttle—a modular, end-to-end cell therapy factory that leverages automation to take in patients' cells, re-engineer them and quickly turn out a finished product ready for infusion.

Related Keywords

Germany ,Berkeley ,California ,United States ,Tokyo ,Japan ,North Carolina ,Netherlands ,Massachusetts ,Holly Springs ,German ,Fabian Gerlinghaus ,Fujifilm Diosynth ,Bristol Myers Squibb ,Novartis ,Cell Shuttle ,Decheng Capital ,Skyviews Life Science ,ஜெர்மனி ,பெர்க்லி ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,டோக்கியோ ,ஜப்பான் ,வடக்கு கரோலினா ,நெதர்லாந்து ,மாசசூசெட்ஸ் ,ஹோலி நீரூற்றுகள் ,ஜெர்மன் ,பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் ,நோவர்த்திச் ,செல் விண்கலம் ,